Tarsus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TARS Tarsus Pharmaceuticals Inc
TXN Texas Instruments Inc
GTH Genetron Holdings Ltd
$NQAT60LMGBPT Nasdaq Austria Energy Large Mid Cap
FICO Fair Isaac Corp
CBDL Cbd Life Sciences Inc
HKXCY Hong Kong Exchanges and Clearing Ltd
TOMZ TOMI Environmental Solutions Inc
GDXD MicroSectors? Gold Miners -3X Inverse Leveraged ETNs
CWK Cushman & Wakefield PLC
Go

Health Care : Pharmaceuticals |
Company profile

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapeutics. The Company's lead product candidate, TP-03, is an investigational eye drop in Phase III to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis (Blephar is a reference to eyelid and itis is a reference to inflammation) is a condition characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. The Company designed TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels.

Closing Price
$17.32
Day's Change
-0.23 (-1.31%)
Bid
--
Ask
--
B/A Size
--
Day's High
18.10
Day's Low
17.25
Volume
(Light)
Volume:
57,294

10-day average volume:
74,858
57,294

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, August 11, 2022
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year Initiated Ersa Phase 2a trial evaluating TP-03 for the treatment of Meibomian Gland Disease (Globe Newswire)

August 05, 2022
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has enrolled the first...(Globe Newswire)

July 25, 2022
Certara Appoints Rosemary Crane as New Independent Board Member

EQNX::TICKER_START (NASDAQ:CERT),(NASDAQ:TARS),(NYSE:CTLT),(NYSE:TEVA), EQNX::TICKER_END Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21...(Globe Newswire)

May 27, 2022
Tarsus to Present at the Jefferies 2022 Healthcare Conference

EQNX::TICKER_START (NASDAQ:TARS), EQNX::TICKER_END Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.